| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 3845- | Moringa, | Protective effects of Moringa oleifera Lam. leaves against arsenic-induced toxicity in mice |
| - | in-vitro, | NA, | NA |
| 3847- | MSM, | Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement |
| - | Review, | Arthritis, | NA |
| 3846- | MSM, | Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy |
| - | Human, | NA, | NA |
| 2484- | mushLions, | Neurotrophic and Neuroprotective Effects of Hericium erinaceus |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3815- | mushLions, | Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines |
| - | Review, | Stroke, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 1573- | MushReishi, | Ganoderma lucidum (Reishi mushroom) for cancer treatment |
| - | Review, | NA, | NA |
| 1997- | Myr, | QC, | Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity |
| - | in-vitro, | Lung, | A549 |
| 5786- | NAD, | Therapeutic potential of NAD-boosting molecules: the in vivo evidence |
| - | Review, | Nor, | NA |
| 2931- | NAD, | NAD+ Repletion Rescues Female Fertility during Reproductive Aging |
| - | in-vivo, | Nor, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 5611- | NaHCO3, | NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells |
| - | vitro+vivo, | HCC, | HepG2 |
| 5620- | NaHCO3, | Tumor acidity: From hallmark of cancer to target of treatment |
| - | Review, | Var, | NA |
| 5619- | NaHCO3, | Safety and efficacy of sodium bicarbonate for treating metabolic acidosis in chronic kidney disease: A systematic review and meta-analysis |
| - | Review, | CKD, | NA |
| 5617- | NaHCO3, | Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells |
| - | vitro+vivo, | NA, | NA |
| 5616- | NaHCO3, | DCA, | Bicarbonate and dichloroacetate: Evaluating pH altering therapies in a mouse model for metastatic breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 5615- | NaHCO3, | immuno, | pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review |
| - | Review, | Var, | NA |
| 5612- | NaHCO3, | immuno, | Neutralization of tumor acidity improves anti-tumor responses to immunotherapies |
| - | vitro+vivo, | Var, | B16-F10 |
| 5610- | NaHCO3, | doxoR, | Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin |
| - | vitro+vivo, | BC, | 4T1 |
| 5609- | NaHCO3, | Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function |
| - | in-vitro, | Var, | NA |
| 5607- | NaHCO3, | Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review |
| - | Review, | Var, | NA |
| 5606- | NaHCO3, | Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer |
| - | Trial, | PC, | NA |
| 5605- | NaHCO3, | A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis |
| - | Trial, | HCC, | NA |
| 5604- | NaHCO3, | Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity |
| - | vitro+vivo, | Melanoma, | B16-BL6 | - | in-vitro, | BC, | 4T1 |
| 5603- | NaHCO3, | immuno, | Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | GBM, | U87MG |
| 5602- | NaHCO3, | immuno, | Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model |
| - | in-vivo, | BC, | 4T1 |
| 5600- | NaHCO3, | Acidosis and Cancer: from Mechanism to Neutralization |
| - | Review, | Var, | NA |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
| 1801- | NarG, | A Narrative Review on Naringin and Naringenin as a Possible Bioenhancer in Various Drug-Delivery Formulations |
| - | Review, | Var, | NA |
| 4225- | NarG, | Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury |
| - | in-vivo, | NA, | NA |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 5254- | NCL, | The magic bullet: Niclosamide |
| - | Review, | Var, | NA |
| 4973- | Nimb, | Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell Lung Cancer Cells |
| - | in-vitro, | NSCLC, | A549 |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 1226- | OLST, | Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation |
| - | vitro+vivo, | GC, | NA |
| 5936- | P, | The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data |
| - | Review, | IBD, | NA |
| 2053- | PB, | 4-Phenyl butyric acid prevents glucocorticoid-induced osteoblast apoptosis by attenuating endoplasmic reticulum stress |
| - | in-vitro, | ostP, | 3T3 |
| 2068- | PB, | Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism |
| - | in-vivo, | Nor, | NA |
| 2061- | PB, | Chemo, | Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | COLO357 | - | in-vitro, | PC, | Bxpc-3 |
| 2063- | PB, | Rad, | Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation |
| - | in-vitro, | GBM, | U87MG | - | NA, | NA, | U251 |
| 2065- | PB, | TMZ, | Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells |
| - | in-vitro, | GBM, | NA |
| 2069- | PB, | Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes |
| - | in-vitro, | Tong, | NA |
| 2070- | PB, | Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 2074- | PB, | Chemo, | The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | H1650 |
| 2077- | PB, | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 2048- | PB, | Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo |
| - | in-vitro, | OS, | CAL27 | - | in-vitro, | Oral, | HSC3 | - | in-vitro, | OS, | SCC4 | - | in-vivo, | NA, | NA |
| 2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
| - | Trial, | GBM, | NA |
| 2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
| - | Review, | Var, | NA |
| 2036- | PB, | Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 2049- | PB, | Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid